Evidence map›Paper›PMID 25083079›Full record

ArticleWorld journal of gastroenterology2014

Nonalcoholic fatty liver disease and the heart in children and adolescents.

Lucia Pacifico, Claudio Chiesa, Caterina Anania, Antonio De Merulis, John Frederick Osborn, Sara Romaggioli, Eugenio Gaudio

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Magnetic Resonance Elastography of Liver: Current Update.Topics in magnetic resonance imaging : TMRI · 2018
    Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Pediatric Non-Alcoholic Fatty Liver Disease.Children (Basel, Switzerland) · 2017
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Endocrine causes of nonalcoholic fatty liver disease.World journal of gastroenterology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Lucia PacificoLucia Pacifico, Caterina Anania, Antonio De Merulis, Sara Romaggioli, Department of Pediatrics and Child Neuropsychiatry, Sapienza University of Rome, 00161 Rome, Italy.
Claudio ChiesaLucia Pacifico, Caterina Anania, Antonio De Merulis, Sara Romaggioli, Department of Pediatrics and Child Neuropsychiatry, Sapienza University of Rome, 00161 Rome, Italy.
Caterina AnaniaLucia Pacifico, Caterina Anania, Antonio De Merulis, Sara Romaggioli, Department of Pediatrics and Child Neuropsychiatry, Sapienza University of Rome, 00161 Rome, Italy.
Antonio De MerulisLucia Pacifico, Caterina Anania, Antonio De Merulis, Sara Romaggioli, Department of Pediatrics and Child Neuropsychiatry, Sapienza University of Rome, 00161 Rome, Italy.
John Frederick OsbornLucia Pacifico, Caterina Anania, Antonio De Merulis, Sara Romaggioli, Department of Pediatrics and Child Neuropsychiatry, Sapienza University of Rome, 00161 Rome, Italy.
Sara RomaggioliLucia Pacifico, Caterina Anania, Antonio De Merulis, Sara Romaggioli, Department of Pediatrics and Child Neuropsychiatry, Sapienza University of Rome, 00161 Rome, Italy.
Eugenio GaudioLucia Pacifico, Caterina Anania, Antonio De Merulis, Sara Romaggioli, Department of Pediatrics and Child Neuropsychiatry, Sapienza University of Rome, 00161 Rome, Italy.
Sapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the last two decades, the rise in the prevalence rates of overweight and obesity explains the emergence of nonalcoholic fatty liver disease (NAFLD) as the leading cause of chronic liver disease worldwide. As described in adults, children and adolescents with fatty liver display insulin resistance, glucose intolerance, and dyslipidemia. Thus NAFLD has emerged as the hepatic component of the metabolic syndrome (MetS) and a strong cardiovascular risk factor even at a very early age. Several studies, including pediatric populations, have reported independent associations between NAFLD and markers of subclinical atherosclerosis including impaired flow-mediated vasodilation, increased carotid artery intima-media thickness, and arterial stiffness, after adjusting for cardiovascular risk factors and MetS. Also, it has been shown that NAFLD is associated with cardiac alterations, including abnormal left ventricular structure and impaired diastolic function. The duration of these subclinical abnormalities may be important, because treatment to reverse the process is most likely to be effective earlier in the disease. In the present review, we examine the current evidence on the association between NAFLD and atherosclerosis as well as between NAFLD and cardiac dysfunction in the pediatric population, and discuss briefly the possible biological mechanisms linking NAFLD and cardiovascular changes. We also address the approach to treatment for this increasingly prevalent disease, which is likely to have an important future global impact on the burden of ill health, to prevent not only end-stage liver disease but also cardiovascular disease.

Indexed as

AdolescentAge FactorsCardiovascular DiseasesChildHeartHumansNon-alcoholic Fatty Liver DiseasePrevalencePrognosisRisk FactorsRisk Reduction BehaviorAtherosclerosisCardiac functionCardiac structureChildrenNonalcoholic fatty liver disease

Identifiers

PMID25083079
PMCPMC4112863
OpenAlexW1594187709

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.